Biotechnology

Aerospace and Life Sciences TIC Market by Sourcing type, Service Type, Application and Region - Forecast to 2025 - ResearchAndMarkets.com

Friday, September 18, 2020 - 4:30pm

The "Aerospace and Life Sciences TIC Market by Sourcing type (In-house and Outsourced services), Service Type (Testing, Inspection and Certification), Application (Aerospace and Life Sciences) and Region - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aerospace and Life Sciences TIC Market by Sourcing type (In-house and Outsourced services), Service Type (Testing, Inspection and Certification), Application (Aerospace and Life Sciences) and Region - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global aerospace and life sciences TIC market is expected to grow at a CAGR of 3.8% from USD 31.3 billion in 2020 to USD 37.8 billion.
  • The TIC market in India is projected to grow at the highest CAGR during the forecast period.
  • Moreover, the R&D from India has helped the increasing the market share of TIC services in the aerospace and life sciences TIC market.

Nemaura Medical Appoints Justin Mclarney as Chief Finance Officer

Friday, September 18, 2020 - 4:11pm

Nemaura Medical, Inc. (NASDAQ: NMRD)(Nemaura or the Company), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces it has appointed Justin Mclarney as Chief Finance Officer, effective September 15, 2020.

Key Points: 
  • Nemaura Medical, Inc. (NASDAQ: NMRD)(Nemaura or the Company), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces it has appointed Justin Mclarney as Chief Finance Officer, effective September 15, 2020.
  • Dr. Faz Chowdhury, Nemaura Medicals Chief Executive Officer commented, We are very pleased to welcome Justin to Nemaura.
  • Mr. Mclarney brings with him a wealth of experience within International Finance, Accounting, and Process Development & Control and has been a Chartered Accountant since 1999.
  • Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.

Global CRISPR & Cas Genes Market Size, Share & Trends Analysis Report 2020-2027: Focus on Vector-based Cas, DNA-free Cas, Cell Line Engineering - ResearchAndMarkets.com

Friday, September 18, 2020 - 4:09pm

The "Global CRISPR & Cas Genes Market Size, Share & Trends Analysis by Product & Service (Vector-based Cas, DNA-free Cas, Cell Line Engineering), Application, End Use, and Segment Forecasts 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CRISPR & Cas Genes Market Size, Share & Trends Analysis by Product & Service (Vector-based Cas, DNA-free Cas, Cell Line Engineering), Application, End Use, and Segment Forecasts 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) genes market size is expected to reach USD 4.88 billion by 2027, expanding at a CAGR of 16.6% from 2020 to 2027.
  • Rise in the adoption of CRISPR technology in epigenetics, therapeutics, human germline editing, plant genome editing, and other fields of biotechnology is expected to drive the market.
  • Presence of a large number of service providers that provide knockout, knock-in, gene repression, gene activation, and other cell line engineering services propel the growth of cell line engineering services.

Coherus BioSciences Announces New Employment Inducement Grants

Friday, September 18, 2020 - 4:01pm

The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Companys board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.

Key Points: 
  • The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Companys board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
  • Headquartered in the United States, Coherus is committed to reducing healthcare system costs and expanding patient access of essential therapeutics.
  • Coherus has commercialized UDENYCA (pegfilgrastim-cbqv) in the United States and received regulatory approval for UDENYCA in the European Union.
  • Coherus is advancing late-stage clinical products CHS-1420, a Humira (adalimumab) biosimilar, Bioeqs Lucentis (ranibizumab) biosimilar and Innovents Avastin (bevacizumab) biosimilar towards commercialization.

Pipeline Therapeutics Appoints Lori Lyons-Williams to its Board of Directors

Friday, September 18, 2020 - 4:00pm

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Lori Lyons-Williams to the companys Board of Directors.

Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Lori Lyons-Williams to the companys Board of Directors.
  • I am thrilled that Lori will be joining the Pipeline board as an independent director, said Carmine Stengone, President & CEO of Pipeline Therapeutics.
  • Im excited to be joining Pipelines Board of Directors not long after the companys lead development candidate, PIPE-505, entered the clinic, said Ms. Lyons-Williams.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.

AIkido Pharma Announces Update On Its Use Of Artificial Intelligence

Friday, September 18, 2020 - 3:00pm

The development of products and tools to provide extensive information on PDA markers to guide personalized medicine.

Key Points: 
  • The development of products and tools to provide extensive information on PDA markers to guide personalized medicine.
  • The assembly of survival associations of individual markers from ONCOLNC.org into sets that will help identify novel targets in PDA.
  • Information about gene and protein function in human PDA patients and human PDA cancer cell lines to help prioritize individual diagnostic markers.
  • AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.

Global Preclinical Stage Partnering Deal Terms and Agreements in Pharma and Biotech Directory 2014-2020 - ResearchAndMarkets.com

Friday, September 18, 2020 - 2:48pm

The "Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020" report has been added to ResearchAndMarkets.com's offering.
  • The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals.
  • This report contains a comprehensive listing of over 1,800 preclinical stage partnering deals announced since 2014 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties.
  • Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 includes:
    Available contracts are listed by:

Global Pharma and Biotech Clinical Stage Partnering Deal Terms and Agreements Report 2014-2020: Comprehensive Listing of Over 2,300 Clinical Stage Partnering Deals - ResearchAndMarkets.com

Friday, September 18, 2020 - 2:39pm

The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020" report has been added to ResearchAndMarkets.com's offering.
  • The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.
  • This report contains a comprehensive listing of over 2,300 clinical stage partnering deals announced since 2014 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties.
  • Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2020 includes:
    Available contracts are listed by:

Global Biotech Partnering Terms and Agreements Directory 2016-2020: Access to Headline, Upfront, Milestone and Royalty Data - ResearchAndMarkets.com

Friday, September 18, 2020 - 2:26pm

The "Global Biotech Partnering Terms and Agreements 2016-2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Biotech Partnering Terms and Agreements 2016-2020" report has been added to ResearchAndMarkets.com's offering.
  • Global Biotech Partnering Terms and Agreements 2016 to 2020 report provides a detailed understanding and analysis of how and why companies enter Biotech partnering deals.
  • The report takes the reader through a comprehensive review Biotech deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Biotech partnering deals.
  • Global Biotech Partnering Terms and Agreements 2016 to 2020 provides the reader with the following key benefits:
    Insight into terms included in a Biotech partnering agreement, with real world examples
    Available deals are listed by:

CURE Media Group Names Christie Santure, B.S.N., RN, OCN, Winner of 2020 Extraordinary Healer® Award for Oncology Nursing

Friday, September 18, 2020 - 2:25pm

CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, has selected Christie Santure, B.S.N., RN, OCN, the winner of the 2020 Extraordinary Healer Award for Oncology Nursing, which honors exceptional nurses for their efforts in the oncology community.

Key Points: 
  • CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, has selected Christie Santure, B.S.N., RN, OCN, the winner of the 2020 Extraordinary Healer Award for Oncology Nursing, which honors exceptional nurses for their efforts in the oncology community.
  • Santure and Farrat were recognized Sept. 17 during the 2020 Extraordinary Healer Award for Oncology Nursing virtual celebration in conjunction with the ONS Bridge Virtual Conference.
  • Founded in 2007, the Extraordinary Healer Award for Oncology Nursing has received hundreds of nominations, and it continues to grow each year.
  • For more information on how to nominate an oncology nurse for the 2021 Extraordinary Healer Award for Oncology Nursing, click here.